-
公开(公告)号：US20140205634A1
公开(公告)日：2014-07-24
申请号：US14176199
申请日：2014-02-10
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Philippe DENOEL , Philippe Vincent HERMAND , Steve LABBE , Jan POOLMAN , Stephane RIOUX
IPC: A61K39/09
CPC classification number: A61K39/092 , A61K2039/55505 , A61K2039/55566 , A61K2039/55572
Abstract: Methods of treating a Streptococcus pneumoniae infection are described herein.
Abstract translation: 本文描述了治疗肺炎链球菌感染的方法。
-
公开(公告)号：US20170056490A1
公开(公告)日：2017-03-02
申请号：US15351847
申请日：2016-11-15
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Ralph Leon BIEMANS , Dominique BOUTRIAU , Philippe DENOEL , Pierre DUVIVIER , Carine GORAJ
IPC: A61K39/085 , A61K47/48
CPC classification number: A61K39/085 , A61K47/6415 , A61K47/646 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.
Abstract translation: 本申请涉及包含与载体蛋白缀合以形成金黄色葡萄球菌5型荚膜糖缀合物的金黄色葡萄球菌5型荚膜糖的免疫原性组合物。
-
公开(公告)号：US20160129101A1
公开(公告)日：2016-05-12
申请号：US14893685
申请日：2014-06-03
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Ralph Leon BIEMANS , Dominique BOUTRIAU , Philippe DENOEL , Pierre DUVIVIER , Carine GORAJ
IPC: A61K39/085 , A61K47/48
CPC classification number: A61K39/085 , A61K47/6415 , A61K47/646 , A61K2039/545 , A61K2039/55566 , A61K2039/57 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.
Abstract translation: 本申请涉及包含与载体蛋白缀合以形成金黄色葡萄球菌5型荚膜糖共轭物的金黄色葡萄球菌5型荚膜糖的免疫原性组合物。
-
公开(公告)号：US20160175423A1
公开(公告)日：2016-06-23
申请号：US15058493
申请日：2016-03-02
Applicant: GlaxoSmithKline Biologicals S.A.
Inventor： Francois-Xavier Jacques BERTHET , Wilfried LJ DALEMANS , Philippe DENOEL , Joelle THONNARD , Christiane FERON , Jan POOLMAN , Georges THIRY , Pierre VOET , Yves LOBET , Guy DEQUESNE
IPC: A61K39/095 , C12N15/10 , C12N15/74
CPC classification number: A61K39/095 , A61K39/145 , A61K47/6911 , A61K2039/522 , A61K2039/55505 , A61K2039/55544 , A61K2039/70 , C07K14/22 , C12N15/102 , C12N15/74
Abstract: The present invention relates to an immuno-protective and non-toxic Gram-negative bleb vaccine suitable for paediatric use. Examples of the Gram-negative strains from which the blebs are made are N. meningitidis, M. catarrhalis and H. influenzae. The blebs of the invention are characterized by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.
Abstract translation: 本发明涉及适用于儿科用途的免疫保护性和无毒革兰氏阴性泡状疫苗。 制作泡沫的革兰氏阴性菌株的实例是脑膜炎奈瑟菌，卡他莫拉菌和流感嗜血杆菌。 本发明的泡沫的特征在于对细菌染色体的一个或多个遗传变化，包括保护性抗原的上调，免疫显性非保护性抗原的下调和LPS的脂质A部分的解毒。
-
公开(公告)号：US20150044253A1
公开(公告)日：2015-02-12
申请号：US14525883
申请日：2014-10-28
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Ralph Leon BIEMANS , Dominique BOUTRIAU , Carine CAPIAU , Philippe DENOEL , Pierre DUVIVIER , Jan POOLMAN
IPC: A61K39/102 , A61K39/29 , A61K39/00 , A61K39/05 , A61K39/08 , A61K39/095 , A61K39/02
CPC classification number: A61K39/385 , A61K39/0017 , A61K39/0018 , A61K39/05 , A61K39/08 , A61K39/092 , A61K39/095 , A61K39/099 , A61K39/102 , A61K39/116 , A61K39/12 , A61K39/145 , A61K39/292 , A61K2039/545 , A61K2039/55 , A61K2039/575 , A61K2039/6037 , A61K2039/62 , A61K2039/627 , A61K2039/70 , C07H3/00 , C12N7/00 , C12N2730/10134 , C12N2760/16234 , C12N2760/16271 , C12N2770/32634 , Y02A50/466 , Y02A50/472 , Y02A50/484
Abstract: The present application discloses an immunogenic composition comprising a Hib saccharide conjugate, at least one additional bacterial, for example N. meningitidis, saccharide conjugate(s), and a further antigen selected from the group consisting of whole cell pertussis and hepatitis B surface antigen, wherein the saccharide dose of the Hib saccharide conjugate is less than 5 μg.
Abstract translation: 本申请公开了一种免疫原性组合物，其包含Hib糖结合物，至少一种额外的细菌，例如脑膜炎奈瑟球菌，糖结合物和选自全细胞百日咳和乙型肝炎表面抗原的另外的抗原， 其中Hib糖共轭物的糖剂量小于5μg。
